Physicians' Academy for Cardiovascular Education
Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.
In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.
ESC 2018 Although aspirin resulted in a reduction of CV events in a primary prevention setting of diabetes patients, this CV benefit was counterbalanced by an increase in bleeding.
ESC 2018 One large randomized trial showed that use of aspirin for primary prevention reduced CV events in a diabetes population but at the cost of bleeding, and another resulted in no CV benefit in individuals with moderate CV risk.
ESC 2018 In overweight or obese patients with CVD or diabetes with CV risk factors, lorcaserin demonstrated to be safe with respect to CV outcomes. Dr Bohula discussed the details of the CAMELLIA-TIMI 61 trial.
ESC 2018 Use of omega-3 fatty acid supplements did not result in reduction of CV outcomes in the ASCEND trial, a large, randomized, long-term trial of diabetes patients.
In overweight and obese patients with HFrEF, treatment with liraglutide led to significant reductions in body weight, HbA1c, and triglyceride levels compared to placebo.
A longitudinal study showed that weight gain does not offset the benefits of smoking cessation on reducing CV and all-cause mortality, even though a temporary increase in the risk of T2DM is seen in quitters.
A nationwide cohort study showed no excess risk of death, stroke and MI in T2DM patients with five risk-factor variables within guideline-recommended target ranges, compared to general Swedish population.
Prof. Carolyn Lam recognizes six mechanisms that play a role in the pathophysiology of HFpEF. She shares evidence why these mechanisms may be targeted for therapy.
In adult T2DM patients, the combination of exenatide and dapagliflozin led to significantly better glycemic control and reductions in weight and SBP compared with monotherapy after 52 weeks.
A randomized, non-inferiority trial showed comparable HbA1c reductions with an intermittent energy restricted diet compared to a continuous energy restricted diet in adult overweight and obese T2DM patients.
A subanalysis of the DiRECT-study found lower liver fat content after a weight loss intervention, and higher insulin secretion in some T2DM patients, suggesting that β cell function can be recovered.
